Opendata, web and dolomites

RARITY SIGNED

RAtional design of canceR ImmunoTherapY: one size does not fit all

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RARITY project word cloud

Explore the words cloud of the RARITY project. It provides you a very rough idea of what is the project "RARITY" about.

anti    multidimensional    mutations    imaging    mainly    detect    immunotherapy    lack    immune    genomic    activate    blockade    15    shortcomings    immunogenic    reactive    transcription    fingerprint    compromised    cancer    revolutionized    novo    malignancies    tissues    minority    lt    therapeutic    benefit    immunotherapies    strategies    selectively    deploying    rarity    employment    modulation    therapy    cells    isolation    regions    cancers    personalized    detectable    provoking    screening    microenvironments    unprecedented    innovative    diagnosed    few    vaccination    preliminary    conducting    applicability    cell    inventoried    tumour    treatment    class    solutions    naturally    events    unannotated    suggest    cytometry    benefits    play    antigens    arise    acquire    ground    distinctive    natural    mass    checkpoint    categorised    thought    breaking    therapies    treatments    technologies    responds    complementary    data    activation    phenotypes    demonstrates    vivo    proteins    exomic    de    ex    patients    translation    induce   

Project "RARITY" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 1˙499˙795 €
 EC max contribution 1˙499˙795 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2024-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 1˙499˙795.00

Map

 Project objective

Checkpoint blockade immunotherapies have revolutionized cancer treatment. However, this immunotherapy only benefits a minority of patients (< 15%), mainly those diagnosed with cancers having many mutations. Furthermore, checkpoint blockade therapy does not selectively activate cancer-reactive T cells. RARITY responds to these shortcomings, aiming to provide innovative solutions for the development of effective immunotherapies for patients who do not benefit from current treatments. The ground-breaking preliminary data included in this application demonstrates that cancer-reactive T cells can be naturally present in so-called non-immunogenic cancers and that they acquire distinctive phenotypes. RARITY will apply state-of-the-art technologies to fingerprint these phenotypes. This will allow the isolation of cancer-reactive T cells from tumour tissues and their employment as highly-effective therapies. Therapeutic vaccination with cancer antigens can also be used to induce T cell responses in patients where natural activation of cancer-specific T cells is not detectable. However, the applicability of vaccination is compromised by the lack of specific targets, particularly in malignancies with few mutations. RARITY will address this problem by deploying a novel class of cancer antigens. An unprecedented screening of non-exomic genomic regions will be done to detect unannotated proteins that arise from de novo transcription and translation events. These proteins can then be targeted by personalized immunotherapies. Finally, thought-provoking findings included in RARITY suggest that immune cell subsets other than T cells play a major role in anti-tumour immune responses. These subsets need to be fully inventoried and categorised so that complementary strategies to T cell immunotherapies can be developed. RARITY will do so by conducting multidimensional analysis of cancer microenvironments using imaging mass cytometry and ex vivo modulation of immune responses.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RARITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RARITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SoftHandler (2019)

Commercial feasibility of an integrated soft robotic system for industrial handling

Read More  

RESOURCE Q (2019)

Efficient Conversion of Quantum Information Resources

Read More  

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More